Navigation Links
New Bone Drug May Prevent Fractures But Raise Clot Risk

It's too soon to say if it outperforms existing drugs, expert says

WEDNESDAY, Feb. 24 (HealthDay News) -- A new drug to fight osteoporosis, the bone condition associated with aging and debilitating fractures, reduces the risk of fractures and the risk of some breast cancers, heart disease and stroke, according to a new study.

But, like other anti-osteoporosis drugs already on the market, the drug -- called lasofoxifene -- also boosts the risk of blood clots, the researchers found. Lasofoxifene, proposed brand name Fablyn, is not yet approved by the U.S. Food and Drug Administration.

Overall, lasofoxifene looks good, according to lead study author Dr. Steven Cummings, professor and director of the San Francisco Coordinating Center at the University of California San Francisco.

But Dr. Carolyn Becker, who wrote an editorial accompanying the study published in the Feb. 25 issue of the New England Journal of Medicine, is taking a wait-and-see approach. "It may turn out to be a dynamite drug, but it's not anything I would rush in to use as a clinician," she said. "There are too many unknowns."

For the study, Cummings and his team assigned 8,556 women who were aged 59 to 80 and had osteoporosis to take a daily dose of the drug (either 0.25 or 0.5 milligrams a day) or a placebo for five years. All had a bone mineral density T score of minus 2.5, considered osteoporosis.

The new drug is in a class of medications known as selective estrogen-receptor modulators (SERM), which act like estrogen in some tissues but anti-estrogen in other. "They act like estrogens when binding to bone cells and don't act like estrogen in the breast [thus not 'feeding' any cancers of the breast]," Cummings said.

Another SERM, already on the market, is raloxifene (Evista).

In the study, the researchers found that lasofoxifene "reduces the risk of all fractures (spinal and elsewhere), breast cancer, heart disease and stroke," Cummings said. "Breast cancer by more than half, nonspinal fractures by about a quarter, which is similar to what other drugs have done, stroke and heart disease by a quarter to a third."

The results he cites are all for the higher dose, 0.5 milligrams a day, when compared to placebo. The higher dose worked better, they found, and is the dose planned for clinical use.

When Cummings looked at adverse events during the follow-up, he found deaths were comparable in the high-dose and placebo group (73 and 65), but more deaths occurred in the low-dose group (90) from any cause.

More women taking the drug developed lung cancer, too -- 28 compared to four in the placebo group. Cummings said that may be related to chance.

Blood clot risk more than doubled on the drug, they found, a risk similar to what is found with estrogen and other SERMs, although the absolute risk was still small.

"The big news for osteoporosis is that lasofoxifene also prevents the fractures that cause most of the disability," Cummings said, referring to non-spinal fractures such as hip, upper arm and pelvis.

But Becker pointed out in her editorial that this effect did not kick in until five years, and the absolute risk reductions were small.

Women with osteoporosis should first consider drugs known as bisphosphonates (Fosamax and others), Cummings said, turning to SERM drugs if they are considered at higher risk.

Cummings has reported receiving consulting fees from pharmaceutical companies including Pfizer, which is developing Fablyn. Becker reports no disclosures.

More information

To learn more about medications for osteoporosis, visit the National Osteoporosis Foundation.

SOURCES: Steven R. Cummings, M.D., professor, director, San Francisco Coordinating Center, University of California, San Francisco; Carolyn Becker, M.D., associate professor, medicine, Harvard Medical School and Brigham and Women's Hospital, Boston; Feb. 25, 2010, New England Journal of Medicine

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Psychiatrys main method to prevent mistaken diagnoses of depression doesnt work: NYU study
2. Bitrex Bitter Safety Additive Exhibiting at the Safe Kids Fair 2010; Making a Bitter Face to Learn about Poisoning Prevention
3. AT&T Foundations $50,000 Donation to National Health Foundation Supports Teen Pregnancy Prevention Program
4. African-Americans attitudes about lung cancer may hinder prevention
5. Sacred Heart Medical Center Cited for Violation of Safety Standards in H1N1 Prevention
6. New Safety Bath and Sill Mats Help Prevent Slip and Fall in Bathrooms - from Martinson-Nicholls
7. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
8. VIDEO from Medialink and AAFA: Asthma PSA Reinforces Prevention of Asthma Symptoms
9. Medical Nurse Training, Inc. Partners With Healthcare Companies to Develop Corporate Branded, Accredited Programs for Patient/Bed Safety and Fall Prevention/Protection
10. Botox May Prevent Some Migraines
11. Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: